Menopause care that goes deeper than a Pap and a script.
Hormones, longevity, sexual health, body composition. The full picture — for the next thirty years.
Menopause isn't a single transition point — it's the start of the longest hormonal chapter of your life. Mt. Baker Medical treats the postmenopausal phase as a 25-to-30-year longevity plan, not a checklist. HRT decisions get re-evaluated annually. Bone density, cardiovascular risk, brain health, metabolic resilience, and sexual health are all on the table at every visit. The goal: you feel like yourself, and you stay that way.
Services we use to treat menopause.
Hormone replacement therapyBioidentical, lab-driven, re-evaluated annuallyWomen's sexual healthGSM, local estradiol, the under-treated dimensionLongevity medicineThe 25–30 year plan after menopauseReady to investigate the root cause?
Thirty minutes with Dr. Scribner. No exam, no charge — just a conversation about what’s actually going on.
Book free consultation →Menopause care that goes deeper than a Pap and a script.
Hormones, longevity, sexual health, body composition. The full picture — for the next thirty years.
Menopause isn't a single transition point — it's the start of the longest hormonal chapter of your life. Mt. Baker Medical treats the postmenopausal phase as a 25-to-30-year longevity plan, not a checklist. HRT decisions get re-evaluated annually. Bone density, cardiovascular risk, brain health, metabolic resilience, and sexual health are all on the table at every visit. The goal: you feel like yourself, and you stay that way.
Perimenopause is over. Now what?
Once you've gone twelve consecutive months without a period, you're postmenopausal. The clinical questions in this phase are different from perimenopause. You're not waiting for the next symptom flare. You're optimizing for the next three decades. That means thinking about HRT in terms of cardiovascular protection, bone density, and brain health — not just symptom control. It means thinking about protein intake, resistance training, and body composition. It means thinking about cancer screening, longevity biomarkers, and how the menopausal hormone shift affects every downstream system. Standard care typically handles the symptom checklist and leaves the longevity work undone. We do both.
What changes after menopause — and what each one needs.
Six systems shift meaningfully after menopause. The workup and treatment plan attend to all six, not just the headline symptoms.
Estrogen loss accelerates bone resorption. Most rapid bone loss happens in the first 5–7 years post-menopause. Untreated, the trajectory leads to osteopenia and osteoporosis decades later.
DEXA scan at baseline, repeat every 2 years. HRT, weight-bearing exercise, vitamin D and K2, protein targets, occasionally pharmacological intervention when warranted.
Estrogen's cardioprotective effect ends at menopause. Cardiovascular disease becomes the leading cause of death in postmenopausal women. ApoB and Lp(a) become more meaningful predictors than total cholesterol.
Full lipid panel including ApoB, Lp(a) (once-in-a-lifetime test), coronary calcium scoring discussion, HRT timing-window consideration, lifestyle and pharmacological levers.
Estradiol affects neuronal energy metabolism and the brain's glucose use. Cognitive symptoms after menopause are common and treatable. The risk window for long-term cognitive change overlaps with the HRT-decision window.
HRT when indicated, sleep optimization, metabolic intervention, B12 and methylation workup, cognitive testing referral if concerns warrant.
Muscle mass becomes harder to maintain — protein targets and resistance training matter more, not less. Visceral fat tends to increase. Body composition changes are independent drivers of cardiovascular and metabolic risk.
InBody scans at baseline and every visit, protein and training targets, GLP-1 therapy when metabolic markers warrant it, ongoing tracking of muscle mass (not just weight).
Genitourinary syndrome of menopause — vaginal dryness, painful sex, urinary symptoms, increased UTI risk — affects most postmenopausal women and is dramatically under-treated. Local vaginal estradiol is highly effective and very safe.
Local estradiol, scream cream, oxytocin troches, frank conversation about libido and arousal, pelvic floor referral when warranted.
Sleep architecture changes after menopause. Mood disorders sometimes emerge or worsen. The response to fixing them is different from premenopausal patterns.
HRT when indicated, sleep workup, mood evaluation, sometimes referral for cognitive behavioral therapy or psychiatric input, ongoing follow-up.
The HRT decision after menopause.
The Women's Health Initiative (WHI) study published in 2002 set HRT use back by twenty years by reporting risk in a way that didn't account for age at initiation or formulation. The reanalyzed data — and a generation of subsequent research — shows that for most women within ten years of menopause, the benefits of HRT (cardiovascular protection, bone density, cognitive function, symptom relief, quality of life) outweigh the risks. The decision is risk-stratified, not absolute.
The factors that go into the decision include: how long you've been postmenopausal, your personal and family history of breast cancer and cardiovascular disease, your current symptom burden, your goals for the next 10–20 years, and your tolerance for the modest risk profile of well-prescribed HRT. We have this conversation in detail at the initial visit and re-evaluate annually as your risk picture evolves. The goal is not to use HRT forever, and not to avoid it on principle — it's to make a deliberate, evidence-based call about a treatment that affects most of the major systems in your body for the next 30 years.
WHI-era menopause care vs modern menopause care.
The default of conventional primary care still reflects the 2002 WHI interpretation. The evidence has moved. The standard of care hasn't always followed.
Common questions about menopause.
What are the signs that you need hormone replacement therapy?
The strongest signals: persistent hot flashes or night sweats that disrupt sleep, vaginal dryness or painful sex (GSM), declining bone density on DEXA, new or worsening cognitive symptoms, mood changes that don't respond to other interventions, and a quality-of-life impact significant enough that the cost-benefit conversation tips toward treatment. HRT isn't reserved for severe symptoms — the long-term protective effects on cardiovascular health, bone density, and cognitive function are real and weigh into the decision even for women with mild symptoms. The signs that you need HRT and the signs that HRT would benefit you are two different questions, and we discuss both at the initial visit.
Is HRT safe after menopause?
For most women within 10 years of menopause and without specific contraindications, modern HRT — bioidentical estradiol and progesterone, transdermal where possible — has a favorable risk-benefit profile. The risks are real but modest and well-characterized: a small increase in breast cancer risk that emerges after 5+ years of combination therapy (and not at all with estrogen alone in women without a uterus), and a small clotting risk that is substantially lower with transdermal vs oral estrogen. Those risks are weighed against the benefits: cardiovascular protection, bone density preservation, cognitive function, symptom relief, sexual health, and quality of life. For women more than 10 years past menopause, the risk-benefit calculation shifts and the conversation is different. We don't prescribe by template; we work through your specific history.
How long does it take HRT to work?
Vasomotor symptoms (hot flashes, night sweats) often improve within 2–4 weeks of starting HRT. Sleep quality typically follows shortly after. Mood, energy, and cognitive symptoms tend to lift over 4–12 weeks. GSM (vaginal dryness, painful sex) responds to local vaginal estradiol within 4–8 weeks of consistent use, sometimes faster. Bone density and cardiovascular benefits are long-term effects that don't have a 'felt' timeline but show up on DEXA and lab markers over 1–3 years. Dosing often needs adjustment in the first 3–6 months to find the right level for you — symptom response, side-effect profile, and labs all inform titration.
What is GSM and how is it treated?
GSM — genitourinary syndrome of menopause — describes the cluster of symptoms that arise from estrogen loss in vaginal, vulvar, and urinary tissues: vaginal dryness, painful sex, vaginal or vulvar irritation, urinary urgency, increased UTI frequency, and bladder leakage. It affects most postmenopausal women and tends to worsen over time without treatment. The most effective treatment is local vaginal estradiol — a cream, ring, or tablet used vaginally — which delivers estrogen directly to the affected tissues with minimal systemic absorption. It's highly effective and very safe, including for many women who are not candidates for systemic HRT. Other options include vaginal DHEA, oxytocin troches, and pelvic floor physical therapy. GSM is dramatically under-treated; most women don't know there's an effective solution.
How does menopause affect bone density?
Estrogen loss accelerates bone resorption (the breakdown side of normal bone turnover), and the most rapid bone loss happens in the first 5–7 years after menopause. Untreated, the trajectory leads to osteopenia in your 60s and osteoporosis in your 70s for a significant percentage of women — which is when fragility fractures (hip, spine, wrist) become a real risk. The screening tool is DEXA (dual-energy X-ray absorptiometry), which we recommend at baseline (around or just after menopause) and repeat every 2 years. The levers are HRT (the most powerful single intervention for postmenopausal bone density), weight-bearing and resistance exercise, adequate protein intake, vitamin D and K2, and pharmacological treatment when warranted.
What labs should I get after menopause?
The annual workup we run on postmenopausal patients includes: full thyroid panel with reverse T3; sex hormones (estradiol, FSH, testosterone, SHBG) if on HRT for dose titration; full lipid panel including ApoB and a one-time Lp(a); fasting insulin, HbA1c, and metabolic markers; hsCRP and ferritin for inflammation; vitamin D, B12, magnesium; DEXA every 2 years; mammogram per current guidelines; coronary calcium scoring or carotid intima-media thickness discussion depending on cardiovascular risk profile; and a discussion of multi-cancer early detection (Galleri) for patients who want broader screening. The point of the annual panel is to track the trajectory across all the systems that menopause affects — not to confirm any single diagnosis.
Ready to plan the next thirty years?
Thirty minutes with Dr. Scribner — no exam, no commitment, no charge. We talk through where you are, what's ahead, and the workup that builds the longevity plan.